ULTRAM ER Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ultram Er, and when can generic versions of Ultram Er launch?
Ultram Er is a drug marketed by Valeant Pharms and is included in one NDA.
The generic ingredient in ULTRAM ER is tramadol hydrochloride. There are thirty-six drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the tramadol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ultram Er
A generic version of ULTRAM ER was approved as tramadol hydrochloride by SUN PHARM INDS INC on June 19th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ULTRAM ER?
- What are the global sales for ULTRAM ER?
- What is Average Wholesale Price for ULTRAM ER?
Summary for ULTRAM ER
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 94 |
| Clinical Trials: | 21 |
| Patent Applications: | 2,442 |
| What excipients (inactive ingredients) are in ULTRAM ER? | ULTRAM ER excipients list |
| DailyMed Link: | ULTRAM ER at DailyMed |
Recent Clinical Trials for ULTRAM ER
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Henry Ford Health System | Phase 4 |
| Medical College of Wisconsin | Phase 2 |
| University of Pennsylvania | Phase 4 |
Paragraph IV (Patent) Challenges for ULTRAM ER
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ULTRAM ER | Extended-release Tablets | tramadol hydrochloride | 300 mg | 021692 | 1 | 2007-09-25 |
| ULTRAM ER | Extended-release Tablets | tramadol hydrochloride | 200 mg | 021692 | 1 | 2007-03-28 |
| ULTRAM ER | Extended-release Tablets | tramadol hydrochloride | 100 mg | 021692 | 1 | 2007-01-08 |
US Patents and Regulatory Information for ULTRAM ER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valeant Pharms | ULTRAM ER | tramadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021692-001 | Sep 8, 2005 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Valeant Pharms | ULTRAM ER | tramadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021692-002 | Sep 8, 2005 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Valeant Pharms | ULTRAM ER | tramadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021692-003 | Sep 8, 2005 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ULTRAM ER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Valeant Pharms | ULTRAM ER | tramadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021692-003 | Sep 8, 2005 | ⤷ Subscribe | ⤷ Subscribe |
| Valeant Pharms | ULTRAM ER | tramadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021692-001 | Sep 8, 2005 | ⤷ Subscribe | ⤷ Subscribe |
| Valeant Pharms | ULTRAM ER | tramadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021692-003 | Sep 8, 2005 | ⤷ Subscribe | ⤷ Subscribe |
| Valeant Pharms | ULTRAM ER | tramadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021692-002 | Sep 8, 2005 | ⤷ Subscribe | ⤷ Subscribe |
| Valeant Pharms | ULTRAM ER | tramadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021692-002 | Sep 8, 2005 | ⤷ Subscribe | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ULTRAM ER
See the table below for patents covering ULTRAM ER around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Slovakia | 76394 | AGENT WITH SUCCESSIVE RELEASE OF EFFECTIVE MATTER AND METHOD OF ITS PREPARATION | ⤷ Subscribe |
| Norway | 20053104 | ⤷ Subscribe | |
| Finland | 122717 | ⤷ Subscribe | |
| Singapore | 50706 | Sustained release compositions and a method of preparing pharmaceutical compositions | ⤷ Subscribe |
| Japan | 3045924 | ⤷ Subscribe | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ULTRAM ER
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0566709 | SPC/GB04/012 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925 |
| 0566709 | C300152 | Netherlands | ⤷ Subscribe | PRODUCT NAME: TRAMADOLI HYDROCHLORIDUM EN PARACETAMOLUM; NAT. REGISTRATION NO/DATE: RVG 28113 20030115; FIRST REGISTRATION: 359 228-3 2002050405 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
